Intravenous immunoglobulins in patients with COVID-19-associated moderate-to-severe acute respiratory distress syndrome (ICAR): multicentre, double-blind, placebo-controlled, phase 3 trial
Aurélien Mazeraud, Matthieu Jamme, Rossella Letizia Mancusi, Claire Latroche, Bruno Mégarbane, Shidasp Siami, Jonathan Zarka, Guy Moneger, Francesco Santoli, Laurent Argaud, Patrick Chillet, Grégoire Müller, Cédric Bruel, Pierre Asfar, François Beloncle, Jean Reignier, Christophe Vinsonneau, Caroline Schimpf, Julien Amour, Cyril Goulenok, Caroline Lemaître, Benjamin Rohaut, Philippe Mateu, S. de Rudnicki, Bruno Mourvillier, Pierre-Louis Declercq, Carole Schwebel, Annabelle Stoclin, Marc Garnier, Benjamin Madeux, Stèphane Gaudry, Karine Bailly, Christian Lamer, Philippe Aegerter, C. Rieu, Khaoussou Sylla, Bruno Lucas, Tarek Sharshar
Topics & Concepts
MedicinePlaceboCoronavirus disease 2019 (COVID-19)Acute respiratory distressSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Respiratory distressDouble blindIntravenous ImmunoglobulinsAntibody2019-20 coronavirus outbreakInternal medicineClinical trialAnesthesiaImmunologyVirologyPathologyOutbreakLungDiseaseInfectious disease (medical specialty)Alternative medicineRespiratory Support and MechanismsCOVID-19 Clinical Research StudiesSepsis Diagnosis and Treatment